Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CLEARSIDE BIOMEDICAL, INC.

(CLSD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2022 01/13/2022 01/14/2022 01/18/2022 01/19/2022 Date
2.33(c) 2.23(c) 2.23(c) 2.19(c) 2.1277 Last
252 437 503 389 930 029 266 247 20 504 Volume
-5.28% -4.29% 0.00% -1.79% -2.84% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 21,3 M - -
Net income 2021 -9,45 M - -
Net cash position 2021 17,1 M - -
P/E ratio 2021 -13,4x
Yield 2021 -
Sales 2022 8,12 M - -
Net income 2022 -24,9 M - -
Net Debt 2022 17,7 M - -
P/E ratio 2022 -5,50x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2021 5,33x
EV / Sales 2022 18,3x
Nbr of Employees 33
Free-Float 88,4%
More Financials
Company
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently... 
More about the company
Ratings of Clearside Biomedical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CLEARSIDE BIOMEDICAL, INC.
2021CLEARSIDE BIOMEDICAL : CLSD-CLS-AX OASIS Results Slide Presentation
PU
2021Clearside Biomedical Says its Eye Disease Drug Meets Primary Endpoint of Safety, Tolera..
MT
2021CLEARSIDE BIOMEDICAL, INC. : Regulation FD Disclosure, Other Events, Financial Statements ..
AQ
2021Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical T..
AQ
2021Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical T..
CI
2021CLEARSIDE BIOMEDICAL, INC.(NASDAQGM : CLSD) added to NASDAQ Biotechnology Index
CI
2021Clearside Biomedical Added to Wedbush Best Ideas List
MT
2021Wedbush Adds Outperform-Rated Clearside Biomedical to Best Ideas List, Citing 'Potentia..
MT
2021Clearside Biomedical to be Added to Nasdaq Biotechnology Index -- Shares Jump in Pre-Ma..
MT
2021Clearside Biomedical Added to the Nasdaq Biotechnology Index
GL
2021CLEARSIDE BIOMEDICAL : November 2021 Corporate Presentation
PU
2021Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at t..
AQ
2021Clearside Biomedical to Participate in Upcoming Investor Events in November and Decemb..
AQ
2021Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corpor..
PU
2021CLEARSIDE BIOMEDICAL, INC. Management's Discussion and Analysis of Financial Condition..
AQ
More news
News in other languages on CLEARSIDE BIOMEDICAL, INC.
2021Clearside Biomedical déclare que son médicament contre les maladies oculaires a atteint..
2021Clearside Biomedical annonce des résultats de sécurité positifs de l'essai clinique de ..
2021Clearside Biomedical ajouté à la liste des meilleures idées de Wedbush
2021Clearside Biomedical étend le contrat de licence de Xipere avec Arctic Vision
2021HISTORIQUE DES RÉACTIONS AUX BÉNÉFIC : Clearside Biomedical Inc, indicateur de suivi de 12..
More news
Analyst Recommendations on CLEARSIDE BIOMEDICAL, INC.
More recommendations
Chart CLEARSIDE BIOMEDICAL, INC.
Duration : Period :
Clearside Biomedical, Inc. Technical Analysis Chart | CLSD | US1850631045 | MarketScreener
Technical analysis trends CLEARSIDE BIOMEDICAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 2,19 $
Average target price 10,80 $
Spread / Average Target 393%
EPS Revisions
Managers and Directors
George M. Lasezkay President, Chief Executive Officer & Director
Charles A. Deignan Chief Financial Officer
William D. Humphries Chairman
Rafael V. Andino Vice President-Engineering & Manufacturing
Thomas A. Ciulla Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
CLEARSIDE BIOMEDICAL, INC.-20.36%131
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873